drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Autologous, gene-modified T cells engineered to express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA/TNFRSF17), enabling TCR-independent recognition and cytolysis of BCMA-positive myeloma cells; administered via IV infusion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous, gene-modified T cells expressing a chimeric antigen receptor bind BCMA on myeloma cells, triggering TCR-independent activation (CD3zeta/costimulatory signaling), proliferation, cytokine release, and cytolytic killing via perforin/granzyme, resulting in depletion of BCMA-positive plasma cells.
drug_name
BCMA CAR-T cells
nct_id_drug_ref
NCT05712083